Related Experiment Video
Updated: Jul 12, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Hepatitis C virus infection in liver allograft recipients
L Caccamo1, M Colledan, B Gridelli
1Istituto di Chirurgia Sperimentale e dei Trapianti Centro Trapianto Fegato, Università di Milano, Ospedale Maggiore I.R.C.C.S., Italy.
Insights
Hepatitis C Virus (HCV) infection significantly impacts liver transplant outcomes. Pre-transplant HCV infection in recipients leads to high recurrence rates, emphasizing the need for careful donor-recipient screening.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C Virus (HCV) infection poses challenges in liver transplantation.
- Understanding HCV transmission dynamics and post-transplant outcomes is crucial for patient management.
Purpose of the Study:
- To determine the prevalence of anti-HCV antibodies in liver donors.
- To assess the risk of HCV infection and re-infection in recipients based on pre-transplant anti-HCV status.
- To evaluate the prevalence of HCV in post-transplant chronic hepatitis.
Main Methods:
- Sera from 42 liver transplant recipients and their donors were tested for anti-HCV antibodies.
- Patients were categorized based on pre-transplant donor (D) and recipient (R) anti-HCV status (D-/R-, D-/R+, D+/R-, D+/R+).
- Liver biopsies were performed on 21 patients with sustained hepatic dysfunction.
Main Results:
- The prevalence of anti-HCV positivity in liver donors was low (3.2%).
- Acquired HCV infection occurred in 9.7% of recipients in the D-/R- group.
- Recurrent HCV hepatitis was high (44.4%) in the D-/R+ group, with 2 deaths due to liver failure.
- HCV was the primary cause of post-transplant chronic hepatitis (77.8%).
Conclusions:
- Pre-transplant HCV infection in recipients is associated with a high incidence of recurrence after liver transplantation.
- HCV remains a significant etiological factor in chronic hepatitis post-liver transplant.
- Careful donor-recipient screening for anti-HCV status is essential to minimize transmission and recurrence.
Abstract:
The impact of HCV infection after liver transplantation remains a topic of discussion. The aims of this study were to define the prevalence of anti-HCV antibodies in liver donors; the risk of acquired HCV infection and HCV re-infection according to the pre-transplant anti-HCV status; the prevalence of HCV infection in post-transplant chronic hepatitis. Sera from 42 recipients with follow up longer than 6 months and their donors were tested for anti-HCV. By results at pre-transplant time patients were classified as follows: donor (D) negative and recipient (R) negative (D-/R-) 31; D-/R+ 9; D+/R- 1; D+/R+ 1. Twenty-one patients with sustained hepatic dysfunction underwent liver biopsy. In group D-/R-, 5 patients showed anti-HCV positivity and 3 (9.7%) of them had acquired HCV hepatitis. In group D-/R+, 6 patients showed persistent anti-HCV positivity and 4 (44.4%) of them had recurrent HCV hepatitis; of these 2 died due to liver failure. The 2 patients of groups D+/R- and D+/R+ had normal liver function. Anti-HCV negative hepatitis was found in 2 patients. The prevalence of anti-HCV positivity in liver donors appeared low (3.2%). Acquired HCV infection rate was 9.7%. Pre-transplant HCV infection led to a high incidence of recurrence (44.4%). HCV was the major etiological agent in post-transplant chronic hepatitis (77.8%).
More Related Videos
Related Concept Videos
Cytomegalovirus Disease
Hepatitis
Viral Hepatitis I: Introduction

